All News
A Convergence of Ideas: COVID19 and ACR
Since the beginning of the pandemic, rheumatologists scrambled to figure out how the SARS-CoV-2 virus will affect their patients with immune mediated inflammatory diseases (IMID). Meeting the needs of patients, managing a practice, and trying to balance a home life have many doctors stressed.
Read Article
Spondyloarthritis at ACR Convergence 2020
There are some really interesting poster and abstract presentations on spondyloarthritis at the ACR Convergence 2020. I’ll be covering these topics, and discussing select individual posters and abstracts during this meeting.
Read Article
4.CIRT: low dose MTX 15 mg/week: transaminitis NNH 6,
cirrhosis NNH 1000
5.LoDoCo2: colchicine prevents MACE: NNT 36
6.ENTRACTE: TCZ vs ETN: for bowel perforation TCZ:
NNH 600
k dao KDAO2011 ( View Tweet)
Year in Review by @JYazdanyMD: #Cardiovascular #Inflammation Reduction Trial provided "unique opportunity to learn about side-effects" of a drug we commonly use.
Low-dose MTX assoc. with small-mod. elevated risk of transaminitis, infection, anaemia & skin cancer.
#ACR20 @RheumNow https://t.co/hNS600Pndr
Mrinalini Dey DrMiniDey ( View Tweet)
How do you monitor HCQ on patients with chronic QTc prolonging medications (ex psychiatric meds)? @JYazdanyMD Year-in-Review #ACR20 @rheumnow
Eric Dein ejdein1 ( View Tweet)
Do you plan to do a skin exam in your RA patients on MTX given new toxicity signal of skin cancer based on CIRT with NNH of 167? @JYazdanyMD #ACR20 Year in Review @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Dr Kevin Wei's study with @ilyakorsunsky @Deepakarao @soumya_boston, Dr. Michael Brenner and others at @BrighamResearch featured in the basic year-in-review at #ACR20 showing Notch signaling importance in synovium from arthritis #ACRambassador
Jeff Sparks jeffsparks ( View Tweet)
What is most important clinical study in last year? #ACR20 @rheumnow
Richard Conway RichardPAConway ( View Tweet)
Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis https://t.co/1kqWeBcEDq #gca #GmCSFinh Novel MOA , big unmet need
Peter Nash drpnash ( View Tweet)
Efficacy & Safety Deucravacitinib (BMS-986165), Oral, Selective TyK2 Inhib in Patients with Active PsA Results from a Phase 2, RDBPC Trial https://t.co/s3V5NtRpuW results-from-a-phase-2-randomized-double-blind-plac/ #psa #tyk2inhib Efficacy in PsA ?top of dose response
Peter Nash drpnash ( View Tweet)
Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators) https://t.co/LGERY3mpe5 #febuxostat #allopurinol #CVS some cardiac reassurance feboxustat
Peter Nash drpnash ( View Tweet)
Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study https://t.co/F86K1Lqou7 #tofacitinib #AS Tofa works in AS , zoster no VTE seen NNH 20(per SAE) NNT 2.5(per ASAS40)
Peter Nash drpnash ( View Tweet)
The #ACR20 Great Debate will feature two experts discussing whether #JAK inhibitors should be used before biologics if methotrexate fails. The session runs Friday, Nov. 6., from 10:00 to 11:00 AM ET. Learn more → https://t.co/I8zTGn0Q06
American College of Rheumatology ACRheum ( View Tweet)
Our daily update is published. States reported record numbers of tests (1.5 million) and cases (116k). Hospitalizations continue their sharp rise. The death toll was 1,124. https://t.co/z3gxwP6EaC
The COVID Tracking Project COVID19Tracking ( View Tweet)
Dr. Dinesh Khanna (@sclerodermaUM): In post-hoc analysis of focuSSed trial of tocilizumab vs. placebo, disease duration, male gender, elevated acute phase reactants, and anti-SCL-70 Ab have a larger beneficial effect on FVC in early SSc-ILD. #ATS2020 #MiniSymposia @UMIntMed 10/
ATS Clinical Problems Assembly ATSCPAssembly ( View Tweet)
One of the many HOT sessions tomorrow #ACR20 I am planning on - IFN is center stage in autoinflammatory/autoimmune/infectious diseases especially-hope they cover IFN autoantibodies!! #COVID19 - @CCalabreseDO @JYazdanyMD @canallab @MaxKonigMD @AdamJBrownMD @TiphaineLft https://t.co/uDauMkGsjX
Leonard Calabrese LCalabreseDO ( View Tweet)
Association Between Changes in Pain Sensitization and Changes in Disease Activity After 12 Weeks of Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis https://t.co/DLGFcDqrus #RA #pain Pain sensitization a management issue - disease control minor benefit
Peter Nash drpnash ( View Tweet)
Very psyched for this session tomorrow at #ACR20 on irAEs- this was a win for Twitter big time-thnxs for the shout out!!! looking for the next cut of data from the @rheum_covid alliance !!! @RheumNow @drdavidliew @CCalabreseDO @cappelliMD @HealioRheum https://t.co/qepFdLhmlV https://t.co/1jSek0sRqT
Links:
Leonard Calabrese LCalabreseDO ( View Tweet)
Happening now! Session 1T001 Opening Session of #ACR20. #ACRambassador Head on over, @ACRheum! https://t.co/eErNDB8pV6
Christina Downey, MD, RhMSUS cdowneymd ( View Tweet)
#ACR20 year in review @JYazdanyMD CIRT trial showing that MTX pneumonitis occurs but is very (very) rare. @RheumNow @jeffsparks @DanielHSolomon https://t.co/UbD4mhHBzq
Richard Conway RichardPAConway ( View Tweet)
